Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2014, and company highlights.
“During the second quarter and recent period, we continued to execute on our expanded ‘Alnylam 5x15’ product development strategy and reported on multiple significant clinical and pre-clinical data sets. As we continue enrolling patients in our APOLLO Phase 3 trial with patisiran, we were pleased to report positive initial data from our ongoing Phase 2 open-label extension (OLE) study, showing sustained knockdown of serum TTR protein levels in addition to a favorable tolerability profile
Help employers find you! Check out all the jobs and post your resume.
